R & D muaj zog
Kev tshawb fawb muaj zog
Peb tau tsim ib qho kev ua haujlwm zoo R & D uas ua rau peb txuas ntxiv txhim kho cov tshuaj tshawb nrhiav hauv cov chaw muaj peev xwm kho tau zoo xws li cov kab mob metabolic, orthopedics, oncology thiab hematology. Los ntawm ntau tshaj 30 xyoo ntawm kev sib sau, peb pab neeg R & D tau sau cov kev paub dhau los hauv kev tshawb nrhiav tshuaj tshiab, kev tshuaj xyuas kev ua tau zoo, txheej txheem thiab kev tshawb fawb zoo, kev tshawb fawb preclinical, kev tshawb fawb soj ntsuam thiab kev tswj xyuas cov ntaub ntawv.
Peb pab pawg R & D muaj kwv yees li 110 tus neeg, ntau dua 60% ntawm cov uas muaj qib master thiab doctoral degree, suav nrog ntau yam kev qhuab qhia. Cov tswv cuab tseem ceeb ntawm pab pawg R & D muaj qhov nruab nrab ntawm ntau tshaj 20 xyoo ntawm kev paub hauv kev lag luam tshuaj. Vim peb muaj peev xwm R & D muaj zog, peb koom nrog ntau lub teb chaws los yog lub xeev kev tshawb fawb tej yaam num. Peb tau ua tiav peb txoj haujlwm tseem ceeb hauv kev tshawb fawb thiab thev naus laus zis hauv tebchaws, thiab peb cov khoom lag luam tau yeej tag nrho 11 lub tebchaws qhuas. Tom qab 30 xyoo ntawm R & D kev siv zog, peb tau tsim rau 6 lub platform kev loj hlob: recombinant protein tshuaj technology platform, peptide tshuaj technology platform, lub tshiab tshuaj-dev cuab yeej ua ke technology platform, antibody tshuaj technology platform, ntev-acting technology platform thiab subcutaneous tshuaj xa technology platform, cia peb mus txuas ntxiv txhim kho thiab ua ntej cov khoom siv pipeline.
Technology Paltform
1.Recombinant protein tshuaj technology platform

Peb siv peb lub cev qhia cov protein uas paub tab, uas yog E. coli qhia qhov system, cov kab mob qhia cov poov xab thiab cov kab mob ntawm tes mammalian, los tsim cov khoom siv kho mob rov ua haujlwm. Siv cov txheej txheem qhia cov protein, peb tau tsim ntau cov tshuaj uas twb muaj nyob rau hauv kev ua lag luam thiab hauv cov theem kho mob (xws li Jilifen, Jijufen thiab JY06 (Jixinfen)).
2.Peptide tshuaj technology platform

Peb tau pib tsim cov tshuaj peptide hauv xyoo 2005 thiab txij li thaum tsim muaj lub peev xwm muaj zog hauv kev tshawb fawb thiab kev tsim kho, kev tsim kho thiab tsim cov tshuaj peptide. Ntxiv rau JY29-2 thiab liraglutide biosimilar tom qab lub npe hu ua Lilupin, peb tseem tab tom tsim cov tshuaj amylin analogs thiab dulaglutide biosimilars siv peb cov tshuaj peptide tshuaj technology platform.
3.Innovative tshuaj-duab siv ua ke technology platform

Peb tau muab cov protein sib xyaw ua ke nrog cov ntaub ntawv lom neeg los tsim kom muaj cov cuab yeej siv tshuaj sib xyaw ua ke. Peb tau tsim Tuam Tshoj thawj zaug kev lag luam rhBMP-2 pob txha kho cov khoom lag luam Guyoudao, thiab siv lub tshuab thev naus laus zis no txuas ntxiv los tsim cov khoom siv kho pob txha tshiab. Cov ntaub ntawv kho pob txha ua haujlwm siab dua.
4.Antibody tshuaj technology platform

Peb cov cuab yeej siv tshuaj tiv thaiv kab mob dav dav npog cov kauj ruam tseem ceeb uas xav tau los tsim cov tshuaj tiv thaiv kab mob, ua kom cov txheej txheem txhim kho tau zoo uas pib nrog kev tshawb pom thiab kev ua kom zoo ntawm cov tshuaj tiv thaiv tshiab. Txog rau tam sim no, peb tau txais kev pom zoo IND rau ob qhov tshuaj ntsuam xyuas tshuaj tiv thaiv kab mob, suav nrog Chav Kawm 1 lub tswv yim tshuaj tiv thaiv kab mob tshiab JY47 thiab cov tshuaj tiv thaiv biosimilar tshuaj ntsuam xyuas JY43. JY47 yog SIRP-specific monoclonal antibody npaj rau kev kho mob ntawm cov qog nqaij hlav, thaum JY43 yog hom phiaj monoclonal antibody npaj rau kev kho mob ntau yam myeloma. Peb kuj tseem tab tom tsim JY41 (Antibody biosimilar), ib qho tshuaj tiv thaiv osteosclerosis npaj rau kev kho mob pob txha. Tsis tas li ntawd, peb txuas ntxiv ua ke thiab txhim kho cov ntaub ntawv ntau npaum ib ncig ntawm cov tshuaj tiv thaiv tshiab. Ntxiv rau kev tsim peb tus kheej cov khoom siv tshuaj tiv thaiv kab mob, peb kuj muab kev tshawb fawb thiab kev tsim kho rau lwm lub tuam txhab tshuaj. Kev tshawb nrhiav tshuaj tiv thaiv kab mob tsim los siv peb cov kev pabcuam R&D tau nkag mus rau theem III kev sim tshuaj.
5.Long-term technology platform

Protein thiab peptide tshuaj feem ntau xav tau kev tswj hwm thiab txhaj tshuaj. Txhawm rau txhim kho cov neeg mob kom yooj yim thiab ua raws li kev siv tshuaj, peb siv ntau yam kev ua yeeb yam ntev, nrog rau kev hloov pauv ntawm fatty acid saw, polyethylene glycol (PEG) kev hloov kho thiab FC fusion, uas tuaj yeem txuas ntxiv ib nrab lub neej ntawm cov tshuaj thiab ua tiav cov txiaj ntsig kev kho mob ntev. Semaglutide biosimilar JY29-2, uas peb tsim thiab hloov kho siv lipidation thev naus laus zis, ua tiav Phase III kev sim tshuaj rau kev kho T2DM thaum Lub Kaum Hli 2023, thiab tau pom zoo rau kev sim tshuaj rau kev kho mob rog thiab rog dhau lub Ib Hlis 2024. Tsis tas li ntawd, peb tau xa daim ntawv thov NDA cov khoom rau May20CSA rau NMPA. (Jixinfen) hloov kho nrog PEGylation thev naus laus zis. Peb kuj muab cov kev pab cuam txhim kho tshuaj preclinical rau lwm lub tuam txhab tshuaj nrog peb cov tshuab ua haujlwm ntev. Kev tshawb nrhiav tshuaj insulin detemir tsim los siv peb cov cuab yeej lipidation tau txais kev pom zoo IND.
6.Subcutaneous tshuaj xa technology platform

Rau kev tswj hwm parenteral, ntau qhov xwm txheej tsis zoo yog cuam tshuam nrog kev tswj hwm txoj hlab ntshav. Hloov mus rau subcutaneous txhaj tshuaj tuaj yeem txo qhov kev pheej hmoo ntawm cov xwm txheej tsis zoo thiab txhim kho cov neeg mob siab rau cov tshuaj. Peb lub platform tsom rau kev xa cov tshuaj subcutaneous siv cov hyaluronidase recombinant. Hyaluronidase tuaj yeem ua rau hydrolyze subcutaneous hyaluronic acid ib ntus, yog li txhim kho qhov tawg thiab nkag mus ntawm cov tshuaj hauv cov ntaub so ntswg thiab txhim kho bioavailability ntawm cov tshuaj. Yog li ntawd, kev sib txuas ntawm hyaluronidase nrog cov tshuaj nquag tso cai rau cov tshuaj loj loj uas yog thawj zaug yuav tsum tau xa los ntawm kev txhaj tshuaj rau hauv cov hlab ntsha, yog li muab cov neeg mob muaj kev nyab xeeb thiab kev xaiv yooj yim dua. Peb tau tsim nws tus kheej tsim recombinant hyaluronidase JY53 thiab cia siab tias yuav xa daim ntawv sau npe tshuaj yeeb tshuaj (DMF) rau JY53 ua ib qho khoom noj rau xyoo 2024. Raws li lub platform no, peb tab tom ua kev tshawb fawb preclinical ntawm daratumumab biosimilar JY43-2. JY43-2 muaj recombinant human hyaluronidase thiab tuaj yeem txhaj tshuaj subcutaneously.
Cov cuab yeej cuab tam
Lub tuam txhab tau txais txiaj ntsig zoo rau kev tsim kho cov cuab yeej cuab tam lub tswv yim, muaj lub tuam txhab kev tswj hwm kev txawj ntse, thiab tau tsim ntau txoj cai los txhawb kev tsim kho thev naus laus zis thiab kev tiv thaiv kev txawj ntse. Lub tuam txhab tau ntsuas raws li patent demonstration enterprise nyob rau hauv Zhejiang xeev nyob rau hauv 2010. Nyob rau hauv Lub kaum hli ntuj 2014, nws tau txais "Intellectual Property Management System Certificate" muab los ntawm Zhongzhi (Beijing) Certification Co., Ltd. Thaum Lub Kaum Hli 2015, nws tau txais daim ntawv pov thawj "Intellectual Property Management System Certificate" los ntawm National Intellectual Property Administration. Lub tuam txhab muab qhov tseem ceeb heev rau kev tiv thaiv cov cuab yeej cuab tam thiab ua tiav cov txheej txheem patent rau R & D cov haujlwm. Peb tuav 15 daim ntawv sau npe patent thiab yim daim ntawv thov patent tseem nyob hauv Suav teb, thiab ob daim ntawv thov PCT tseem tos. Peb tau txais ntau yam khoom plig thiab kev lees paub, suav nrog 3 patents uas yeej "Tuam Tshoj Zoo Tshaj Plaws Patent Award".

